Botulinum toxin type A

Generic Name
Botulinum toxin type A
Brand Names
Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva
Drug Type
Biotech
Chemical Formula
-
CAS Number
93384-43-1
Unique Ingredient Identifier
0A6JH35GMQ
Background

In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other conditions. A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm, and hyperhidrosis.

Indication

Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.

In addition to the above indications, botulinum toxin A is used for the following conditions: treatment of adults with symptomatic overactive bladder with or without incontinence, treatment of incontinence in adult patients who are not candidates for anticholinergic therapy, treatment of Neurogenic Detrusor Overactivity (NDO) in patients over 5 years who cannot undergo anticholinergic therapy. Botulinum toxin A is indicated for the prevention of chronic migraines, for the treatment of muscle spasms, cervical dystonia, axillary hyperhidrosis, strabismus, and disorders of the 7th cranial nerve.

Off-label, botulinum toxin A is used for a variety of conditions such as temporomandibular joint (TMJ) disorders and myofascial pain, neurogenic thoracic outlet syndrome, epicondylitis, post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, neuropathic pain, spinal cord injury, and bladder pain.

Associated Conditions
Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis
Associated Therapies
-

Botulinum Toxin in the Treatment of Raynaud's

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2010-11-04
Last Posted Date
2014-04-21
Lead Sponsor
Emory University
Target Recruit Count
10
Registration Number
NCT01233999
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

Botulinum Toxin A for Herpes Labialis

First Posted Date
2010-10-21
Last Posted Date
2020-12-21
Lead Sponsor
DeNova Research
Target Recruit Count
20
Registration Number
NCT01225341
Locations
🇺🇸

DeNova Research, Chicago, Illinois, United States

A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity

Phase 3
Completed
Conditions
Interventions
First Posted Date
2010-09-20
Last Posted Date
2017-02-28
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
109
Registration Number
NCT01205451
Locations
🇨🇳

GSK Investigational Site, Shanghai, China

Botox in the Healing of Surgical Wounds of the Neck

Phase 2
Completed
Conditions
Interventions
First Posted Date
2010-08-09
Last Posted Date
2024-08-21
Lead Sponsor
Nova Scotia Health Authority
Target Recruit Count
40
Registration Number
NCT01177358
Locations
🇨🇦

Queen Elizabeth II Hospital, Halifax, Nova Scotia, Canada

Botulinum Toxin as a Novel Treatment for Prevention of Post-Traumatic Elbow Stiffness

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2010-05-24
Last Posted Date
2015-03-27
Lead Sponsor
Columbia University
Target Recruit Count
18
Registration Number
NCT01129583
Locations
🇺🇸

Columbia University Medical Center, New York, New York, United States

Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

First Posted Date
2010-04-21
Last Posted Date
2019-05-03
Lead Sponsor
Allergan
Target Recruit Count
315
Registration Number
NCT01107392

Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity

Phase 3
Completed
Conditions
Interventions
First Posted Date
2010-03-24
Last Posted Date
2010-03-24
Lead Sponsor
Sunnybrook Health Sciences Centre
Target Recruit Count
57
Registration Number
NCT01091727
Locations
🇨🇦

Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Calcitonin Gene-related Peptide Levels in Chronic Migraine

Phase 4
Completed
Conditions
Interventions
First Posted Date
2010-02-19
Last Posted Date
2013-02-12
Lead Sponsor
Cady, Roger, M.D.
Target Recruit Count
20
Registration Number
NCT01071096
Locations
🇺🇸

Clinvest, Springfield, Missouri, United States

🇺🇸

Island Neurological Associates, P.C., Plainview, New York, United States

Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

First Posted Date
2010-02-08
Last Posted Date
2020-08-28
Lead Sponsor
Revance Therapeutics, Inc.
Target Recruit Count
90
Registration Number
NCT01064518
Locations
🇺🇸

Dermatology Research Institute, LLC, Coral Gables, Florida, United States

Effects of Botulinum Toxin in Cervical Dystonia

First Posted Date
2010-01-26
Last Posted Date
2015-04-17
Lead Sponsor
Henry Ford Health System
Target Recruit Count
7
Registration Number
NCT01056861
Locations
🇺🇸

Henry Ford Hospital, Detroit, Michigan, United States

© Copyright 2024. All Rights Reserved by MedPath